{"id":4299,"date":"2025-03-31T18:12:03","date_gmt":"2025-03-31T18:12:03","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/posaconazole-txt\/"},"modified":"2025-03-31T18:12:03","modified_gmt":"2025-03-31T18:12:03","slug":"posaconazole-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/posaconazole-txt\/","title":{"rendered":"Posaconazole.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nTriazole antifungal agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>400 mg twice daily with food or 240 mL of a nutritional supplementOr 200 mg 4 times a day without food Oropharyngeal candidiasis severe infection or in immunocompromised patients: Loading dose of 200 mg once a day on the first day, then 100 mg once a day for 13 daysProphylaxis of invasive fungal infections: 200 mg 3 times a day

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :700.8<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>98<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <0.2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1774 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :20\u201366 (average 35)\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antidepressants: avoid concomitant use with reboxetine\n
  • Antibacterials: rifamycins may reduce posaconazole concentration; avoid concomitant administration unless benefit outweighs risk; rifabutin concentration increased\n
  • Anti-epileptics: phenytoin, carbamazepine, phenobarbital and primidone may reduce posaconazole concentration \u2013 avoid concomitant administration unless benefit outweighs risk\n
  • Antimalarials: avoid concomitant administration with artemether\/lumefantrine\n
  • Antipsychotics: increased risk of ventricular arrhythmias with pimozide and sertindole \u2013 avoid concomitant use; possibly increase quetiapine levels \u2013 reduce dose of quetiapine\n
  • Antivirals: possibly increases saquinavir levelsAnxiolytics and hypnotics: increases midazolam levels\n
  • Ciclosporin: increases posaconazole concentration. Posaconazole can increase ciclosporin concentration, \u2013 dose reduction may be required\n
  • Ergot alkaloids: may increase ergot alkaloid concentration leading to ergotism \u2013 avoid concomitant administrationLipid-lowering drugs: possibly increased risk of myopathy with atorvastatin or simvastatinSirolimus: may increase concentration of sirolimus \u2013 adjust sirolimus dose as required according to levelsSulphonylureas: posaconazole can decrease glucose concentrations, monitor glucose levels in diabetic patients\n
  • Tacrolimus: concentration of tacrolimus increased \u2013 reduce dose of tacrolimus\n
  • Ulcer-healing drugs: cimetidine may reduce posaconazole concentration by 39% \u2013 avoid concomitant administration unless benefit outweighs risk; drugs which reduce gastric acidity may reduce bioavailability of posaconazoleVinca alkaloids: may increase vinca alkaloid concentration leading to neurotoxicity \u2013 avoid concomitant administration unless benefit outweighs risk. It is advised to reduce the dose of the vinca alkaloid\n
  • Tacrolimus: increases C max and AUC by 121% and 358% respectively of tacrolimus \u2013 reduce tacrolimus dose to about a third of current dose and adjust as required.594 PosAConAZoLE

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Use with caution in people with arrhythmias, electrolyte disturbances QT prolongation, sinus bradycardia and cardiomyopathyContains 7 g of glucose per 800 mg daily dose. Measure liver function tests as moderate increases have been noted.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Triazole antifungal agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4299","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4299"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4299\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}